

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Multiple sheets used when necessary)

NOV 19 2007

SHEET 1 OF 2

Application No.	10/830071
Filing Date	April 23, 2004
First Named Inventor	Gadde, et al.
Art Unit	1614
Examiner	Henley III, Raymond J.
Attorney Docket No.	OREX.009C1

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
<i>[Signature]</i>	1	6262049	07-17-2001	Coffin et al.	
<i>[Signature]</i>	2	6437147	08-20-2002	Andersen et al.	
<i>[Signature]</i>	3	2002-0090615	06-11-2002	Rosen et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
<i>[Signature]</i>	4	WO 00/50020	08-31-2000	McElroy, Susan L.		
<i>[Signature]</i>	5	WO 02/09694	02-07-2002	Plata-Salaman et al.		
<i>[Signature]</i>	6	WO 03/097046 A1	11-27-2003	Gadde et al.		
<i>[Signature]</i>	7	WO 2004/024096 A2	03-25-2004	Shellenberger, M. Kent		
<i>[Signature]</i>	8	WO 2006/017504	02-16-2006	Weber et al.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
<i>[Signature]</i>	9	Ayala et al, "Weight Loss Associated With the Administration of Zonisamide", A Compendium of Posters and Platform Sessions for ZONEGRAN™ and DIASTAT®, Presented at the Annual Meeting 2000 of the American Epilepsy Society, December 1-6, 2000, Los Angeles, California	
<i>[Signature]</i>	10	Erfuth, et al. "Bupropion as add-on strategy in difficult-to-treat bipolar depressive patients", Neuropsychobiology, vol. 45, no. Supplement 1, March 2002, pages 33-36	
<i>[Signature]</i>	11	Kirov, et al. Add-on topiramate reduces weight in overweight patients with affective disorders: a clinical case. BMC Psychiatry, 5:19, 8 pp. (2003)	
<i>[Signature]</i>	12	Kushner, et al. "Obesity pharmacology: past, present, and future.", Current Opinion in Gastroenterology, March 2002, pages 213-220	
<i>[Signature]</i>	13	Penn, et al., "Pharmacotherapy of obesity in the near term.", Current Opinion in Endocrinology and Diabetes 2003 United States, 2003, pages 311-316	
<i>[Signature]</i>	14	POTTER, et al. "Sustained Weight Loss Associated with 12-month topiramate Therapy" Epilepsia, Raven Press Ltd. New York, vol 38, No. Suppl 8, 1997, Page 97	
<i>[Signature]</i>	15	Rotzinger et al., "Metabolism of some 'second' and 'fourth' generation antidepressants: iprindole, viloxazine, bupropin, mianserin, maprotiline, trazadone, nefazodone, and vanlafaxine.", Cellular and Molecular Neurobiology, 1999, 19, page 430	
<i>[Signature]</i>	16	Tutka et al, "Convulsant and anticonvulsant effects of bupropion in mice", European Journal of Pharmacology, 2004, pages 117-120	

Examiner Signature

Date Considered

2/3/08

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.